A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks
This article was originally published in The Pink Sheet Daily
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
You may also be interested in...
Some experts say a study in CF patients with the 508del mutation could not pass IRB muster, but others see an opportunity to answer the question of whether two drugs are needed or one will suffice.
Kalydeco raced to market for cystic fibrosis, but effort to get ‘breakthrough’ approval with lumacaftor for much larger patient population may have FDA worrying about the meaningfulness of pivotal efficacy results.
Obese patients who are severely ill with a high BMI and co-morbidities, and who are highly motivated to try a new therapy and willing to pay for it out-of-pocket, will be targeted for Saxenda.